Symbols

CYTH(Delisted)

Cyclo·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CYTH

Cyclo Therapeutics, Inc.

A clinical-stage biotechnology company that develops cyclodextrin based products

Industry

Established Date

08/09/1990

Listing Date

12/09/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cyclotherapeutics.com

Security Type

Common stock

Office address

6714 NW 16th Street, Suite B, Gainesville, FL 32653

Business

Introduction

Cyclo Therapeutics, Inc., was established on August 9, 1990. The company is a clinical-stage biotechnology company that develops cyclodextrin-based products to treat diseases.

Company Financials

EPS

CYTH has released its 2024 Q2 earnings. EPS was reported at -0.21, versus the expected -0.15, missing expectations. The chart below visualizes how CYTH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CYTH has released its 2024 Q3 earnings report, with revenue of 233.77K, reflecting a YoY change of -52.82%, and net profit of -8.83M, showing a YoY change of -85.12%. The Sankey diagram below clearly presents CYTH's revenue sources and cost distribution.